Lurra Therapeutics

Lurra Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for complex neuropsychiatric and neuroendocrine disorders. The company's lead program, LR-01, is a small molecule antagonist of the growth hormone secretagogue receptor (GHSR), which is the primary receptor for the hormone ghrelin. This therapeutic approach aims to address hyperphagia and metabolic dysfunction in patients with Prader-Willi Syndrome, a rare genetic disorder characterized by life-threatening hunger. Founded by industry veterans with a track record in CNS drug development, Lurra is also exploring the potential of its candidates in broader metabolic indications such as obesity. The company is backed by leading life science venture capital firms including ARCH Venture Partners and Foresite Capital.